Zacks Investment Research lowered shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) from a hold rating to a sell rating in a research report sent to investors on Friday.

According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “

PSTI has been the subject of several other reports. Maxim Group raised Pluristem Therapeutics from a hold rating to a buy rating and set a $2.00 target price for the company in a report on Monday, June 19th. HC Wainwright set a $4.00 target price on Pluristem Therapeutics and gave the company a buy rating in a report on Thursday, August 17th. Finally, ValuEngine lowered Pluristem Therapeutics from a sell rating to a strong sell rating in a report on Friday, September 1st. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $3.19.

Pluristem Therapeutics (PSTI) opened at 1.54 on Friday. The company’s market capitalization is $150.11 million. Pluristem Therapeutics has a 52 week low of $1.04 and a 52 week high of $1.65. The stock’s 50 day moving average price is $1.20 and its 200 day moving average price is $1.28.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at

A hedge fund recently raised its stake in Pluristem Therapeutics stock. Renaissance Technologies LLC increased its holdings in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 9.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,553,800 shares of the biotechnology company’s stock after acquiring an additional 129,000 shares during the period. Renaissance Technologies LLC owned about 1.62% of Pluristem Therapeutics worth $1,911,000 at the end of the most recent quarter. Institutional investors own 4.47% of the company’s stock.

About Pluristem Therapeutics

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.